Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| CELG | Celgene Corporation | -0.53% | 87.99 | 1.3% | $894.47m | |
| AMGN | Amgen Inc. | 0.04% | 191.31 | 1.2% | $560.48m | |
| ONCE | Spark Therapeutics, Inc. | 0.33% | 113.96 | 11.2% | $458.43m | |
| GILD | Gilead Sciences, Inc. | -0.93% | 65.02 | 0.9% | $450.52m | |
| BIIB | Biogen Inc. | -1.28% | 325.65 | 1.3% | $354.96m | |
| BPTH | Bio-Path Holdings, Inc. | -5.48% | 27.79 | 190.1% | $296.94m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -1.66% | 407.60 | 2.6% | $280.72m | |
| ILMN | Illumina, Inc. | -1.31% | 305.78 | 3.5% | $269.47m | |
| VRTX | Vertex Pharmaceuticals Incorporated | -0.32% | 187.48 | 1.9% | $245.27m | |
| SRPT | Sarepta Therapeutics, Inc. | -1.20% | 126.82 | 15.4% | $210.77m | |
| EXAS | Exact Sciences Corporation | -3.44% | 91.93 | 25.3% | $194.56m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -1.90% | 133.51 | 2.0% | $181.24m | |
| A | Agilent Technologies, Inc. | -0.16% | 80.97 | 1.6% | $153.74m | |
| IONS | Ionis Pharmaceuticals, Inc. | 1.25% | 79.52 | 8.3% | $101.55m | |
| BMRN | BioMarin Pharmaceutical Inc. | -1.24% | 93.36 | 4.3% | $97.41m |
Company Profile
Epizyme, Inc. is a clinical-stage biopharmaceutical company, which engage in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. It also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.